Loading...
XSHE
300016
Market cap652mUSD
Dec 05, Last price  
8.20CNY
1D
1.61%
1Q
-20.85%
Jan 2017
-33.41%
IPO
71.36%
Name

Beijing Beilu Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300016 chart
P/E
338.09
P/S
4.69
EPS
0.02
Div Yield, %
Shrs. gr., 5y
0.11%
Rev. gr., 5y
3.73%
Revenues
984m
+10.42%
83,940,018125,728,776232,090,873177,222,067216,810,922182,051,933196,701,996273,979,343331,615,821439,980,365491,430,959498,860,618522,538,130608,053,473819,119,389827,337,626843,901,446765,881,882890,718,122983,554,462
Net income
14m
P
9,140,06512,291,56227,668,38626,053,62434,863,24442,772,51544,211,75163,038,70565,971,72086,768,93832,579,24416,379,483118,816,656147,761,859342,438,319174,701,969125,514,72011,283,927-71,757,14013,651,677
CFO
163m
+160.84%
19,647,35012,275,853057,911,73237,514,83945,726,98922,856,05841,369,95142,107,53680,853,23476,167,184144,924,876175,754,189156,808,658176,002,788108,726,227127,812,75762,497,843163,020,886
Dividend
May 25, 20230.07 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Beijing Beilu Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products. The company's products include contrast agents, central nervous system products, and oral anti-diabetic drugs. Beijing Beilu Pharmaceutical Co., Ltd. also produces precision medicine. The company was founded in 1992 and is based in Beijing, China.
IPO date
Oct 30, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT